1887

Abstract

Purpose. Cytological and histological cervical screening methods for human papillomavirus may be subjective. Current guidelines recommend the use of direct human papillomavirus screening by molecular methods in conjunction with cytology for the detection of high-risk human papillomavirus types with carcinogenic potential. In this study, we compared the performance of the molecular Cepheid Xpert HPV test to the FDA-approved HC2 High-Risk HPV DNA Test on samples from patients presenting for cervical screening, regardless of the cytology results, in which cervical cell samples were originally collected for Papanicolaou (Pap) smear specimens in Becton Dickinson (BD) SurePath preservative fluid.

Methodology. Cervical cells were obtained for Pap smear specimens from 343 women attending Qatif Central Hospital in Saudi Arabia for cervical cancer screening using a Cytobrush Plus GT and immersed in BD SurePath preservative fluid in BD SurePath collection vials. The study was carried out between December 2015 and July 2016.

Results. The Xpert HPV test was positive in 27 (7.9 %) of the samples. The HC2 High-Risk HPV DNA Test was positive in 32 (9.3 %) of the samples. The most common HPV types according to the Xpert HPV test were HPV other types, either alone (n=15) or in combination with HPV16 (n=3). The overall concordance rate between the tests was 98.5 %. The positive concordance was 84.4 %.

Conclusion. The Xpert HPV test is convenient to use on cervical cell samples collected for Pap smear specimens in BD SurePath preservative fluid within an hour and is a viable alternative to the HC2 High-Risk HPV DNA Test for HPV testing.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000723
2018-03-26
2019-10-21
Loading full text...

Full text loading...

/deliver/fulltext/jmm/67/5/676.html?itemId=/content/journal/jmm/10.1099/jmm.0.000723&mimeType=html&fmt=ahah

References

  1. Burd EM. Human papillomavirus laboratory testing: the changing paradigm. Clin Microbiol Rev 2016;29:291–319 [CrossRef][PubMed]
    [Google Scholar]
  2. Chan PK, Picconi MA, Cheung TH, Giovannelli L, Park JS. Laboratory and clinical aspects of human papillomavirus testing. Crit Rev Clin Lab Sci 2012;49:117–136 [CrossRef][PubMed]
    [Google Scholar]
  3. Bernard HU, Burk RD, Chen Z, van Doorslaer K, Zur Hausen H et al. Classification of papillomaviruses (PVs) based on 189 PV types and proposal of taxonomic amendments. Virology 2010;401:70–79 [CrossRef][PubMed]
    [Google Scholar]
  4. Hampl M. Prevention of human papilloma virus-induced preneoplasia and cancer by prophylactic HPV vaccines. Minerva Med 2007;98:121–130[PubMed]
    [Google Scholar]
  5. Centers for Disease Control and Prevention (CDC) 2017; Genital HPV Infection - Fact Sheet. www.cdc.gov/std/hpv/stdfact-hpv.htm [accessed 19. 09. 17]
  6. Arbyn M, Tommasino M, Depuydt C, Dillner J. Are 20 human papillomavirus types causing cervical cancer?. J Pathol 2014;234:431–435 [CrossRef][PubMed]
    [Google Scholar]
  7. Koshiol J, Lindsay L, Pimenta JM, Poole C, Jenkins D et al. Persistent human papillomavirus infection and cervical neoplasia: a systematic review and meta-analysis. Am J Epidemiol 2008;168:123–137 [CrossRef][PubMed]
    [Google Scholar]
  8. Oakeshott P, Aghaizu A, Reid F, Howell-Jones R, Hay PE et al. Frequency and risk factors for prevalent, incident, and persistent genital carcinogenic human papillomavirus infection in sexually active women: community based cohort study. BMJ 2012;344:e4168 [CrossRef][PubMed]
    [Google Scholar]
  9. Darragh TM, Colgan TJ, Thomas Cox J, Heller DS, Henry MR et al. The Lower Anogenital Squamous Terminology Standardization project for HPV-associated lesions: background and consensus recommendations from the College of American Pathologists and the American Society for Colposcopy and Cervical Pathology. Int J Gynecol Pathol 2013;32:76–115 [CrossRef][PubMed]
    [Google Scholar]
  10. Karjane N, Chelmow D. New cervical cancer screening guidelines, again. Obstet Gynecol Clin North Am 2013;40:211–223 [CrossRef][PubMed]
    [Google Scholar]
  11. Vegunta S, Files JA, Wasson MN. Screening women at high risk for cervical cancer: special groups of women who require more frequent screening. Mayo Clin Proc 2017;92:1272–1277 [CrossRef][PubMed]
    [Google Scholar]
  12. Meijer CJ, Berkhof H, Heideman DA, Hesselink AT, Snijders PJ. Validation of high-risk HPV tests for primary cervical screening. J Clin Virol 2009;46:S1–S4 [CrossRef][PubMed]
    [Google Scholar]
  13. Arbyn M, Snijders PJ, Meijer CJ, Berkhof J, Cuschieri K et al. Which high-risk HPV assays fulfil criteria for use in primary cervical cancer screening?. Clin Microbiol Infect 2015;21:817–826 [CrossRef][PubMed]
    [Google Scholar]
  14. Einstein MH, Smith KM, Davis TE, Schmeler KM, Ferris DG et al. Clinical evaluation of the cartridge-based GeneXpert human papillomavirus assay in women referred for colposcopy. J Clin Microbiol 2014;52:2089–2095 [CrossRef][PubMed]
    [Google Scholar]
  15. Rabaan AA, Taylor DR, Dawamneh MF, Al-Tawfiq JA. Comparison of Xpert®HPV and Hybrid Capture®2 DNA Test™ for detection of high-risk HPV infection in cervical atypical squamous cells of undetermined significance. J Infect Public Health 2017;10:219–223 [CrossRef][PubMed]
    [Google Scholar]
  16. Altman DG. Practical Statistics for Medical Research London, UK: Chapman and Hall; 1991
    [Google Scholar]
  17. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics 1977;33:159–174 [CrossRef][PubMed]
    [Google Scholar]
  18. Alsbeih G, Ahmed R, Al-Harbi N, Venturina LA, Tulbah A et al. Prevalence and genotypes' distribution of human papillomavirus in invasive cervical cancer in Saudi Arabia. Gynecol Oncol 2011;121:522–526 [CrossRef][PubMed]
    [Google Scholar]
  19. Alsbeih G. HPV infection in cervical and other cancers in Saudi Arabia: implication for prevention and vaccination. Front Oncol 2014;4:65 [CrossRef][PubMed]
    [Google Scholar]
  20. Bondagji NS, Gazzaz FS, Sait K, Abdullah L. Prevalence of high-risk human papillomavirus infections in healthy Saudi women attending gynecologic clinics in the western region of Saudi Arabia. Ann Saudi Med 2013;33:13–17 [CrossRef][PubMed]
    [Google Scholar]
  21. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S et al. Human papillomavirus type distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J Cancer 2007;121:621–632 [CrossRef][PubMed]
    [Google Scholar]
  22. Al-Badawi IA, Al-Suwaine A, Al-Aker M, Asaad L, Alaidan A et al. Detection and genotyping of human papilloma virus in cervical cancer specimens from Saudi patients. Int J Gynecol Cancer 2011;21:907–910 [CrossRef][PubMed]
    [Google Scholar]
  23. Castle PE, Solomon D, Wheeler CM, Gravitt PE, Wacholder S et al. Human papillomavirus genotype specificity of hybrid capture 2. J Clin Microbiol 2008;46:2595–2604 [CrossRef][PubMed]
    [Google Scholar]
  24. Kurian EM, Caporelli ML, Baker S, Woda B, Cosar EF et al. Cervista HR and HPV 16/18 assays vs hybrid capture 2 assay: outcome comparison in women with negative cervical cytology. Am J Clin Pathol 2011;136:808–816 [CrossRef][PubMed]
    [Google Scholar]
  25. Zhao C, Yang H. Approved assays for detecting HPV DNA—design, indications, and validation. CAP Today 2012;26:40–44
    [Google Scholar]
  26. Arbyn M, Depuydt C, Benoy I, Bogers J, Cuschieri K et al. VALGENT: a protocol for clinical validation of human papillomavirus assays. J Clin Virol 2016;76:S14–S21 [CrossRef][PubMed]
    [Google Scholar]
  27. Cuschieri K, Geraets D, Cuzick J, Cadman L, Moore C et al. Performance of a cartridge-based assay for detection of clinically significant human papillomavirus (HPV) infection: lessons from VALGENT (Validation of HPV Genotyping Tests). J Clin Microbiol 2016;54:2337–2342 [CrossRef][PubMed]
    [Google Scholar]
  28. Mbulawa ZZA, Wilkin T, Goeieman BJ, Jong E, Michelow P et al. Prevalence of Anal Human Papillomavirus (HPV) and Performance of Cepheid Xpert and Hybrid Capture 2 (hc2) HPV assays in South African HIV-infected women. Am J Clin Pathol 2017;148:148–153 [CrossRef][PubMed]
    [Google Scholar]
  29. Castle PE, Smith KM, Davis TE, Schmeler KM, Ferris DG et al. Reliability of the Xpert HPV assay to detect high-risk human papillomavirus DNA in a colposcopy referral population. Am J Clin Pathol 2015;143:126–133 [CrossRef][PubMed]
    [Google Scholar]
  30. Guerendiain D, Moore C, Wells L, Conn B, Cuschieri K. Formalin fixed paraffin embedded (FFPE) material is amenable to HPV detection by the Xpert(®) HPV assay. J Clin Virol 2016;77:55–59 [CrossRef][PubMed]
    [Google Scholar]
  31. Donà MG, Rollo F, Pichi B, Spriano G, Pellini R et al. Evaluation of the Xpert® HPV assay in the detection of Human Papillomavirus in formalin-fixed paraffin-embedded oropharyngeal carcinomas. Oral Oncol 2017;72:117–122 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000723
Loading
/content/journal/jmm/10.1099/jmm.0.000723
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error